Midwest Capital Advisors LLC Lowers Holdings in Eli Lilly and Company $LLY

Midwest Capital Advisors LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 14.5% during the second quarter, Holdings Channel.com reports. The firm owned 236 shares of the company’s stock after selling 40 shares during the period. Midwest Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $184,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. Precedent Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 15.3% during the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock worth $229,000 after purchasing an additional 39 shares during the period. Capital Advisors Inc. OK increased its holdings in Eli Lilly and Company by 6.8% in the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after buying an additional 429 shares in the last quarter. Family CFO Inc purchased a new position in Eli Lilly and Company in the second quarter valued at $54,000. Duquesne Family Office LLC increased its holdings in Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after buying an additional 32,640 shares in the last quarter. Finally, Corient IA LLC acquired a new position in Eli Lilly and Company in the 1st quarter worth about $570,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 2.6%

Shares of LLY stock opened at $833.08 on Monday. The stock’s fifty day moving average is $742.42 and its two-hundred day moving average is $765.55. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a market capitalization of $788.47 billion, a P/E ratio of 54.45, a PEG ratio of 1.18 and a beta of 0.47. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s revenue for the quarter was up 37.6% on a year-over-year basis. During the same quarter last year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Gabrielle Sulzberger purchased 117 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director directly owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Daniel Skovronsky bought 1,000 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the purchase, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 4,514 shares of company stock valued at $2,894,841. Insiders own 0.14% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on LLY shares. Leerink Partnrs cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. JPMorgan Chase & Co. decreased their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 16th. Wall Street Zen lowered Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Finally, The Goldman Sachs Group lifted their target price on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $948.06.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.